ISSUE 106
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others.1-3 Resistance testing is now recommended when antiretroviral drugs are started.4 Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov.
Antiretroviral treatment regimens usually include a "backbone" and a "base". The backbone is typically two nucleoside reverse transcriptase inhibitors (NRTIs). The base can be a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI),
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 106a
Electronic, downloadable article - $45